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Malignant melanoma (MM) is the most aggressive and life-threatening
form of skin cancer. It is characterized by an extraordinary metastasis
capacity and chemotherapy resistance, mainly due to melanoma cancer
stem cells (CSCs). To date, there are no suitable clinical diagnostic, prog-
nostic or predictive biomarkers for this neoplasia. Therefore, there is an
urgent need for new MM biomarkers that enable early diagnosis and effec-
tive disease monitoring. Exosomes represent a novel source of biomarkers
since they can be easily isolated from different body fluids. In this work, a
primary patient-derived MM cell line enriched in CSCs was characterized
by assessing the expression of specific markers and their stem-like proper-
ties. Exosomes derived from CSCs and serums from patients with MM
were characterized, and their metabolomic profile was analysed by high-
resolution mass spectrometry (HRMS) following an untargeted approach
and applying univariate and multivariate statistical analyses. The aim of
this study was to search potential biomarkers for the diagnosis of this dis-
ease. Our results showed significant metabolomic differences in exosomes
derived from MM CSCs compared with those from differentiated tumour
cells and also in serum-derived exosomes from patients with MM com-
pared to those from healthy controls. Interestingly, we identified similarities
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between structural lipids differentially expressed in CSC-derived exosomes
and those derived from patients with MM such as the glycerophospho-
choline PC 16:0/0:0. To our knowledge, this is the first metabolomic-based
study aimed at characterizing exosomes derived from melanoma CSCs and
patients’ serum in order to identify potential biomarkers for MM diagno-
sis. We conclude that metabolomic characterization of CSC-derived exo-
somes sets an open door to the discovery of clinically useful biomarkers in
this neoplasia.
1. Introduction
Malignant melanoma (MM) is a highly aggressive
form of skin cancer whose incidence continues increas-
ing worldwide at a great rate. It is known that this
aggressiveness is mainly due to intratumoral hetero-
geneity. In fact, tumour cells are hierarchically orga-
nized and sustained by a subpopulation of cells,
known as cancer stem cells (CSCs, or tumour-initiating
cells), which possess stem-like functional properties
such as self-renewal ability and multipotency [1,2].
They are responsible for tumour initiation, mainte-
nance, progression, metastasis and recurrence. In addi-
tion, CSCs are remarkably resistant to radiotherapy
and chemotherapy as a consequence of their particular
biology. Moreover, the CSC phenotype is not a rigid
state and the intratumoral heterogeneity of cancer also
extends to CSC characteristics, mainly due to tumour
microenvironment (TME) [3]. In particular, malignant
melanoma CSCs can be identified by the expression of
specific markers and functional assays, and their stem-
like properties have been demonstrated in vitro and
in vivo [4,5].
Although significant efforts have been made in the
last years, identification of useful diagnostic, prognos-
tic and predictive biomarkers in MM remains challeng-
ing. Several candidate biomarkers have been proposed,
but few have reached clinical application [6]. Thus, it
is important to discover specific useful biomarkers and
develop methods that can sensitively detect this neo-
plasia at subclinical metastatic stages.
Recent investigations confirm that extracellular vesi-
cles (EVs) and exosomes play a major role in cancer
development. They have been recently defined as smal-
ler EVs (sEVs) as a general term, according to minimal
information for studies of extracellular vesicles
(‘MISEV’) guidelines [7] proposed by the International
Society for Extracellular Vesicles (ISEV). By transfer-
ring their cargo to target cells of different lineage, can-
cer cell-derived exosomes are able to induce pathways
involved in cancer initiation, sustenance, progression
and metastasis [8]. They support tumour progression
by promoting angiogenesis, immune system modula-
tion and tumour parenchyma remodelling [9,10]. In
addition, EVs are also released by CSCs, influencing
their surrounding niche. Indeed, CSC-EVs can regulate
direct crosstalk with other neoplastic cells or can mod-
ify normal surrounding cells to promote immune
tumour escape, tumour growth and metastasis. Several
studies have demonstrated that CSC-derived EVs play
a key role in tumour progression [11].
Exosomes have been involved in the metastatic
organotropism mediated by the integrins present in
their surface, and therefore, exosomal integrins could
be used to predict organ-specific metastasis [12].
Malignant melanoma-derived exosomes are involved in
the metastatic dissemination to regional lymph nodes
[13] and distant organs by promoting the generation of
premetastatic niches [14]. Melanoma-derived exosomes
contribute to metastatic invasion by carrying messen-
ger proteins (e.g. the oncoprotein c-MET) educating
bone marrow-derived cells towards a pro-metastatic
phenotype or influencing the behaviour of immune
cells [15].
Importantly, the release of exosomes and other EVs
into the different body biofluids allows their detection,
being a major source of secreted biomarkers in circula-
tion [12,16–18]. Since cancer cells exhibit enhanced
production of exosomes, their concentrations are
increased in body fluids of cancer patients compared
with healthy controls [8]. Thus, exosomes (and other
EVs) could represent a rich source of noninvasive
biomarkers for the diagnosis and prognosis of cancers,
including MM, as well as therapeutic targets
[17,19,20].
In this context, metabolomics as emerging ‘omic’
research technology represents a potential tool for
biomarkers’ discovery. Metabolomics refers to the sys-
tematic identification and quantification of the com-
plete set of low molecular weight metabolites, known
as metabolome, which are context-dependent and vary
according to the physiology, developmental or patho-
logical state of a cell, tissue or organism [21]. The
study of the complete metabolome is technically
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challenging, due to its diversity, and multiple strategies
are employed to provide a broad metabolic coverage.
In this regard, mass spectrometry (MS) is the gold
standard analytical platform for metabolomics, as it
provides high sensitivity, versatility and reproducibility
[18,21,22]. In order to extract useful biological infor-
mation from large and complex data sets generated by
mass spectrometers, univariate (t-test, ANOVA) and
multivariate (PCA, PLS-DA) statistical analyses are
used [18,23].
Over the last decade, several studies using omic
technologies have enhanced the development and vali-
dation of biomarkers currently used in the diagnosis,
prognosis and treatment response prediction in MM
[24], but unfortunately none of the metabolites identi-
fied as potential biomarkers has been proven to be
clinically useful so far. Some metabolomic studies have
evaluated metabolic changes in melanoma using vari-
ous analytical techniques in both in vivo and in vitro
models, but mainly using gas chromatography–mass
spectrometry (GC-MS) [25] or nuclear magnetic reso-
nance (NMR) [26], not many of them have been car-
ried out using liquid chromatography–mass
spectrometry (LC-MS) [27].
Here, we have characterized a patient-derived MM
cell population enriched in CSCs and have analysed
the metabolomic profile of exosomes derived from
these MM cells and from serum of patients with MM
using a high-resolution mass spectrometry untargeted
approach. To our knowledge, we report for the first-
time differences in exosome metabolomic profile from
CSC-enriched melanospheres versus MM-differentiated
cells. We also report metabolomic differences between
serum-derived exosomes from patients with MM at
several stages of the disease compared with those
derived from healthy controls.
2. Materials and methods
2.1. Cell culture and CSC enrichment
The human primary Mel1 MM cell line comes from a
malignant metastatic melanoma (stage M1a) skin
biopsy (BBSPA-Mel#1) and was provided by the Bio-
bank of the Andalusian Public Health System (Spain).
This cell line is hypotriploid (complex karyotype with
multiple numerical and structural chromosome abnor-
malities), MelA-positive, p53-positive and S100-posi-
tive, and has high tumorigenic ability. Mel1 adherent
cells were maintained in standard culture conditions.
Enriched Mel1 CSC subpopulations were obtained
after culturing as primary and secondary spheroids in
serum-free medium and in anchorage-independent con-
ditions [28]. Mel1 adherent cells were cultured in a
humid incubator at 37 °C and 5% CO2, with DMEM
(Dulbecco’s modified Eagle’s medium) (Sigma-Aldrich,
St. Louis, MO, USA) supplemented with 10% heat-in-
activated fetal bovine serum (FBS) (Gibco, Grand
Island, NY, USA) and 1% penicillin/streptomycin (P/
S) (Sigma-Aldrich) in 75-cm2 flask culture (Nunc, Ros-
kilde, Denmark), unless otherwise indicated. FBS was
inactivated by heating at 56 °C for 45 min. Cells were
assayed for mycoplasma contamination. Enriched
Mel1 CSC subpopulations were obtained as follows:
for primary spheroids, culture cells were collected by
centrifugation (352 g for 10 min) and the pellet was
resuspended twice in PBS (phosphate-buffered saline).
Then, resuspended cells were plated in serum-free
sphere culture medium (DMEM:F12, 1% P/S, B27,
10 µgmL1 ITS, 1 µgmL1 hydrocortisone,
4 ngmL1 heparin, 20 ngmL1 EGF, 10 ngmL1
FGF, 10 ngmL1 IL6, 10 ngmL1 HGF) in ultra-low
adherence 6-well plates (Corning, Corning, NY, USA)
for 72 h. For the secondary sphere culture, cells from
primary spheroids were collected by centrifugation
(1500 r.p.m. for 10 min), and then, the pellet was
resuspended in DMEM F12 sphere medium mechani-
cally disrupted with a pipette and by syringing three to
five times through a sterile 25-gauge needle. After that,
cells were plated, resuspended and incubated for 72 h
in sphere culture medium in ultra-low adherence 6-well
plates.
2.2. Sphere-forming assay
To determine the self-renewal ability of the Mel1 CSC
population, a sphere-forming assay was performed
[29]. Mel1 cell lines were grown as spheroids as
described above: 2.5 9 105 cells were washed with
PBS and resuspended in sphere culture medium in
ultra-low adherence 6-well plates (Corning). Spheres
> 75 µm diameter were counted after 3 days by light
microscopy. For the secondary sphere-forming assay,
2.5 9 105 single cells derived from primary spheroids
were plated and resuspended in sphere culture medium
in ultra-low adherence 6-well plates. Diameters were
measured using the IMAGEJ software.
2.3. Colony-formation assay
The clonogenic capability of Mel1 CSCs was deter-
mined by a colony-formation assay in soft agar as pre-
viously described [29] with minor modifications.
Briefly, 104 cells coming from secondary spheroids
were seeded in 0.4% cell agar base layer, which was
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on top of 0.8% base agar layer in 6-well culture plates.
Then, cells were incubated for 23 days at 37 °C and
5% CO2, adding 100 µL of DMEM (10% FBS, 1%
P/S) every 1–2 days. Cell colony formation was then
examined under a light microscope after staining with
0.1% iodonitrotetrazolium chloride (Sigma-Aldrich).
The size of colonies was measured using IMAGEJTM soft-
ware (Rasband, W.S., ImageJ, U. S. National Insti-
tutes of Health, Bethesda, MD, USA).
2.4. ALDEFLOUR assay and phenotypic
characterization by flow cytometry
The analysis of CD20 and CD44 surface markers and
the ALDH1 activity were performed using a Becton
Dickinson FACSCanto II Flow Cytometer from the
CIC Scientific Instrumental Centre (University of
Granada) as previously described [29]. Briefly, ALDE-
FLUOR assays (Stem Cell Technologies, Vancouver,
BC, Canada) to detect ALDH1 activity in viable cells
were performed according to the manufacturer’s
instructions. Cells were suspended in ALDEFLUOR
assay buffer containing ALDH1 substrate (BAAA,
1 lmolL1 per 1 9 106 cells) and incubated for
45 min at 37 °C in darkness. Diethylaminobenzalde-
hyde (DEAB) was used as an ALDH1 inhibitor to set
ALDH1 gates. The bright fluorescent ALDH1-express-
ing cells were detected in the green fluorescent channel
(520–540 nm). Cell surface levels of CD44 and CD20
were determined with anti-human antibodies CD44-
phycoerythrin (PE) and CD20-allophycocyanin (APC)
(Miltenyi Biotec, Bergisch Gladbach, Germany),
respectively. The bright fluorescent PE and APC were
detected in red (564–606 nm) and blue (650–670 nm),
respectively. All samples were analysed on a FACS-
Canto II (BD Biosciences, San Jose, CA, USA) using
the FACSDIVA software.
2.5. Side population assays
Hoechst 33342 exclusion (side population) assays were
carried out as previously described [30] to analyse cells
overexpressing ABC transporters. Single-cell suspen-
sion obtained from parental cell lines and melano-
spheres were stained with Hoechst 33342 (Sigma-
Aldrich) dye. As negative controls, verapamil (Sigma-
Aldrich) was used for maintaining the efflux channel
closed, inhibiting the capacity to efflux Hoechst 33342
by cells. The bright fluorescent cells were measured by
flow cytometry in Hoechst blue (440/40) and Hoechst
red (695/40) of a FACScan Aria III (BD Biosciences)
using FACSDIVA software from the CIC Scientific
Instrumental Centre (University of Granada). Cells
with the ability to efflux Hoechst 33342 were consid-
ered as the side population (SP).
2.6. Serum sample collection and preparation
Serum samples were obtained from the Oncology Ser-
vice at the University Hospital Virgen de las Nieves of
Granada and University Hospital San Cecilio of Gran-
ada (Spain). The ethics committee from both hospitals
approved the study (number: 32140085), and all clini-
cal investigations were conducted according to the
principles expressed in the Declaration of Helsinki
(‘Ethical Principles for Medical Research Involving
Human Subjects’). Written informed consent was
obtained from all patients and controls before their
enrolment in the study. Samples were obtained from
serum of patients with MM (MMPs) (n = 20) and
healthy controls (HCs) (n = 14). MMPs presented dif-
ferent stages of the disease, namely stage I (n = 5),
stage II (n = 5), stage III (n = 5) and stage IV (n = 5).
Samples were collected in BD vacutainer SSTII
advanced tubes (Becton Dickinson, Franklin Lakes,
NJ, USA) with silica to activate clotting of the speci-
men, incubated at room temperature for 30 min and
centrifuged for 10 min at 1400 g. Afterwards, the
supernatant (around 1 mL) was carefully aspirated
and stored at 80 °C until the examination.
2.7. Exosome isolation and purification
For exosome isolation, Mel1 cells were cultured in 75-cm2
flasks culture in standard anchorage-dependent culture
conditions with DMEM supplemented with 1% P/S and
10% heat-inactivated exosome-depleted FBS, until 80%
confluence. FBS was depleted of bovine exosomes by
ultracentrifugation at 100 000 g for 70 min [12]. Exo-
somes were also isolated from Mel1 CSCs: a total of
3 9 106 cells were cultured as primary and, then, as sec-
ondary spheroids in anchorage-independent and serum-
free conditions, as described above. Supernatant fractions
collected from cell cultures after 72 h were centrifuged at
500 g for 10 min to remove any cell contamination and
debris. Exosomes from cell-free culture supernatants were
purified by sequential centrifugation as previously
described by Costa-Silva et al. [31] with minor modifica-
tions. Briefly, to remove any possible apoptotic bodies,
dead cells and large cell debris, the supernatants were first
spun at 10 000 g for 40 min. Exosomes were collected by
ultracentrifugation at 100 000 g for 80 min. Exosome pel-
lets were washed in 35 mL PBS and pelleted again by
ultracentrifugation at 100 000 g for 80 min (Beckman
SW28 Rotor). In addition, serum-derived exosomes from
MMPs and HCs were isolated following the same
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protocol described above, but washing the exosome pel-
lets in 10 mL PBS. The final pellet was resuspended in
100 lL of PBS and stored frozen at 80 °C for further
analyses. Repeated freezing and thawing of the exosome
suspensions were avoided.
2.8. Transmission and scanning electron
microscopy
Transmission electron microscopy (TEM) and scanning
electron microscopy (SEM) analyses were performed at
the Centro de Instrumentacion Cientıfica (CIC, Univer-
sity of Granada). For TEM and SEM, samples were neg-
atively stained with uranyl acetate as follows: a 30 lL
drop of the exosome sample was placed on a carbon-
coated 300-mesh grid and allowed to adsorb at room tem-
perature for 5 min. The grids were then washed in drops
of ultrapure water for 1 min. Adsorbed exosomes were
negatively stained by placing the grids on a drop of 1%
uranyl acetate in aqueous suspension for 1 min. The
excess fluid was slightly drained with filter paper, and
then, sample grids were dried at room temperature for
6 min. The preparations were examined with a LIBRA
120 PLUS transmission electron microscope (Carl Zeiss
SMT, Oberkochen, Germany) at an acceleration voltage
of 120 kV, and the HITACHI, S-510 scanning electron
microscope. Then, the samples were determinate with the
Edwin-Rontec microanalysis system.
In addition, pellets obtained from CSC cultures were
immersed in 4% paraformaldehyde and 0.1 M PBS for
4 h at 4 °C and washed in sucrose in 0.1 M PBS over-
night. The fractions were incubated by increased alco-
hol concentrations and were cut in semi-thin sections
at 0.5 µm with tissue processor (TP1020; Leica, Wet-
zlar, Germany).
2.9. Atomic force microscopy
Atomic force microscopy (AFM) analyses were per-
formed at the Centro de Instrumentacion Cientıfica
(CIC, University of Granada). For AFM, purified exo-
somes were diluted 1 : 10 in deionized water. A 10 lL
drop of exosome suspension was adsorbed to freshly
cleaved mica sheets at room temperature for 10 min
and rinsed with deionized water to remove salt precipi-
tates. The sheets were then completely dried under a
gentle stream of argon gas (Ar). The preparations were
examined with an NX20 Atomic Force Microscope
(Park Systems, Suwon, South Korea), and images were
visualized and processed using the PARK SYSTEMS XEI
software (Park Systems, Suwon, South Korea). Mea-
surements were carried out with ACTA cantilevers
(40 Nm1) and in noncontact mode.
2.10. Western blot analysis
Exosome pellets were isolated from 100 mL of cell culture
supernatants of adherent cells and CSCs and from
600 µL of patients’ serum. The final pellets were resus-
pended in 100 lL of PBS and stored at 4 °C for further
protein quantification. The protein concentrations were
measured using the BCA Protein Assay Kit (Pierce,
Rockford, IL, USA) according to the manufacturer’s
instructions. Proteins extracts (30 lg) were denatured at
95 °C for 5 min in loading buffer (containing Tris – pH
6.8, SDS, glycerol, b-mercaptoethanol and bromophenol
blue). Proteins were subjected to 4–20% Mini-PRO-
TEAN TGX (Bio-Rad, Hercules, CA, USA) gel together
with Precision Plus ProteinTM Kaleidoscope Prestained
Protein Standards (Bio-Rad). The samples were trans-
ferred to a nitrocellulose membrane (Trans-Blot, Mini
Format, Bio-Rad) using a transfer apparatus according
to the manufacturer’s protocols (standard programme:
25 V for 30 min) (Bio-Rad). After incubation with 5%
skimmed milk in PBS-Tween 0.1% for 1 h at room tem-
perature, the membranes were incubated overnight with
antibodies against CD9 (dilution 1/1500; eBioscience, San
Diego, CA, USA), CD63 (dilution 1/500; Santa Cruz
Biotechnology, Dallas, TX, USA), CD271 (dilution 1/
500; Abcam, Cambridge, UK) and Alix (dilution 1/1000;
Cell Signaling, Danvers, MA, USA). Membranes were
then incubated with conjugated goat anti-mouse sec-
ondary antibody and goat anti-rabbit secondary antibody
for 2 h, and signals were detected using the ECL-PLUS y
ECL PRIME (Amersham Biosciences, Little Chalfont,
UK). The bands were visualized with medical photo-
graphic films (AGFA, Mortsel, Belgium).
2.11. Exosome size analysis
Analyses were performed on NanoSight NS500 Instru-
ments (Malvern Instruments, Malvern, UK). The
instrument was equipped with a 488-nm laser, a high-
sensitivity CMOS camera and a syringe pump. Exo-
somes were diluted 1 : 1000 in PBS buffer to obtain a
concentration range (1–10 9 108 particlesmL1). The
measurements were analysed using the NTA2.3 software
(Malvern) after filming three 60-s videos.
2.12. Immunogold labelling by transmission
electron microscopy
Immunogold labelling of exosomes was carried out at
the Andalusian Centre for Nanomedicine (Bionand,
Malaga, Spain). Exosome suspensions were put on
copper grid with formvar–carbon and incubated for
15 min at RT. They were dried slightly and diluted in
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15 µL of 2% paraformaldehyde in 0.1 M PBS and
incubated for 10 min. The samples were transferred to
a 15 µL drop of 2% BSA in 0.1 M PBS, plus the pri-
mary antibody anti-human CD63 clone H5C6 (RUO)
(Becton Dickinson) diluted 1/500 and incubated for
1.5 h at room temperature within a humid chamber.
After several PBS washes, the grid was incubated with
the anti-mouse IgG (whole molecule)-gold 10 nm sec-
ondary antibody (Sigma-Aldrich) and incubated 1 h at
room temperature within a humid chamber. The sam-
ples were marked with a negative stain by using 15 lL
of 1% uranyl acetate in Milli-Q water for 15 s. The
preparations were examined with a LIBRA 120 PLUS
transmission electron microscope (Carl Zeiss SMT,
Oberkochen, Germany).
2.13. LC-HRMS analysis of exosomes
The metabolomic analyses of exosomes isolated from
cell culture supernatant and patients’ serum samples
were performed in Fundacion MEDINA (Centro de
Excelencia en Investigacion de Medicamentos Inno-
vadores en Andalucıa) as described by Garcıa-Fontana
et al. [32] with minor modifications. Exosome samples
were kept at 4 °C during the analytical process. Sam-
ple preparation for LC-HRMS analysis was performed
as follows. Exosome samples were thawed on ice and
vortexed. Proteins were removed from exosome sus-
pension using methanol (1 : 3 exosomes : methanol),
shaken (60 s), sonicated (1 min) and shaken again.
Samples were then centrifuged at 22 600 g for 15 min
at 4 °C. Supernatants were collected and dried under
an N2 air stream. Dried samples were reconstituted in
90 lL of mobile phase (50% H2O and 50% acetoni-
trile at 0.1% of formic acid) and transferred to the
analytical vials. Samples were stored at 4 °C and anal-
ysed in quadruplicate within 24 h of reconstitution
using AB SCIEX TripleTOF 5600 quadrupole time-of-
flight mass spectrometer (Q-TOF-MS) (AB SCIEX,
Concord, ON, Canada) coupled to an high-perfor-
mance liquid chromatography (HPLC) system, in posi-
tive electrospray ionization (ESI) mode.
Before HRMS analysis, chromatographic separation
was performed by Agilent Series 1290 LC system (Agi-
lent Technologies, Santa Clara, CA, USA), equipped
with a reverse-phase Atlantis T3 HPLC C18 column
(C18: 2.1 mm 9 150 mm, 3 mm) (Waters, Milford,
MA, USA). For each sample, 5 lL was injected into
the HPLC system. Samples were injected randomly in
order to prevent any possible time-dependent changes
in the chromatographic profiling. Blank solvent (BS)
and quality control (QC) samples were injected inter-
spersed in the sequence run. The QC samples were
prepared by pooling an equal volume of all exosome
samples and injected every seven samples in order to
check the stability and performance of the system. The
BS samples were also run interspersed in the sequence
to identify possible impurities of the solvents or extrac-
tion procedure and to check carryover contamination
from intense analytes. Generic parameter settings for
chromatographic separation and MS detection were
used to obtain specific metabolomic fingerprints of the
exosome preparations.
HRMS analysis was carried out using an informa-
tion-dependent acquisition (IDA) method to collect
full-scan MS and MS/MS information simultaneously.
The method consisted of high-resolution survey spectra
from m/z 50 to m/z 1600, and the eight most intense
ions were selected for acquiring MS/MS fragmentation
spectra after each scan. An Automated Calibration
Delivery System performed an exact mass calibration
prior to each analysis.
2.13.1. Data set creation
PEAKVIEW software (AB SCIEX) was used in order to
assess the analytical drift in terms of mass and retention
time shift. MARKERVIEW software (version 1.2.1.1; AB
SCIEX) was used for processing the LC-HRMS raw data.
This software performs peak detection, alignment and
data filtering, generating a feature table which defines
measured m/z, retention time (RT) and integrated ion
intensity. An automated algorithm in the RT range 0.8–
19 min and m/z range 50–1600 was used for data mining.
The intensity threshold of extraction was established at
100 counts per second. RT and m/z tolerances of 0.1 min
and 15 p.p.m., respectively, were used for peak alignment.
Background noise was removed by using a specific tool of
MARKERVIEW software. The analytical replicates of each
sample were averaged.
2.13.2. Analytical validation
Quality control distribution on PCA plot was used for
analytical validation prior to the following analysis.
After that, different approaches of data normalization
(normalization by a QC reference sample, non-normal-
ized data, sum and median normalization), data trans-
formation (logarithmic and cubic root transformation)
and scaling (autoscaling and Pareto scaling) were eval-
uated in order to define which combination provides a
better grouping of QC samples on PCA plot and a
normal distribution of the data. Variables with unac-
ceptable reproducibility (RSD > 30%) or detected in
less than 50% of QC samples were also rejected from
the data matrix.
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2.13.3. Data treatment
Statistical analyses were carried out using MetaboAna-
lyst 3.0 Web Server [23] as previously described [32].
Briefly, after data set creation, raw data were normal-
ized (median normalization), transformed (cube root
transformation) and scaled (Pareto scaling) in order to
achieve a more Gaussian-type distribution [33]. Then,
filtering according to significant differences was done
based on statistical analysis including both univariate
(UVA) and multivariate (MVA). Statistical analyses
were carried out to filter variables (metabolites) that
are significantly different between the groups com-
pared. UVA assesses the statistical significance of each
peak/variable separately, while MVA takes into
account the combination of the effects of multiple
variables. For UVA, a double filtering procedure with
t-test (P-value < 0.05) and fold change (FC > 1.5) was
applied in order to identify differentially expressed
mass signals between BS and exosome samples. This
first filtering allowed removing background noise and
preserving the peaks from true biological samples.
Then, an ANOVA or t-test-based filtering (P-
value < 0.05) was used to detect differential metabo-
lites between the sample groups, providing a quality
criterion to assess variable relevance for further data
analysis. For MVA, principal component analysis
(PCA) and partial least squares regression (PLS-DA)
were carried out after ANOVA or t-test filtering. PCA
was applied to assess quality of the analytical system
performance. PLS-DA allowed discriminating variables
that are responsible for variation between the compar-
ison groups. For statistical validation, quality descrip-
tion by goodness of fit (R2) and goodness of
prediction (Q2) was used. A powerful model for diag-
nostics should show high values of R2 and Q2 but also
not vary more than 0.2–0.3. For metabolomic data,
R2 > 0.7 and Q2 > 0.4 are considered acceptable values
[33]. The models were also validated using 10-fold
cross-validation. Receiver operator characteristic
(ROC) curve analyses were carried out to evaluate the
clinical utility of the metabolites selected as potential
biomarkers [34]. The AUC provided in this work are
flipped (1-AUC), and consequently, they are always
presented as being > 0.5 independently of the case–
control ratios.
2.13.4. Metabolite identification
In the next step, a stepwise search of the m/z and frag-
mentation spectrum of the possible candidates was
performed on several online databases (METLIN,
HMDB, LIPID MAPS, MassBank and PubChem),
NIST MS/MS library (NIST14, version 2.2, National
Institute of Standards and Technology 2014) and sci-
entific literature. The mass tolerance was set at
10 ppm. For automatic MS and MS/MS elemental
formula estimation, the Formula Finder plug-in of
PEAKVIEW software (AB SCIEX) was used, setting the
mass tolerance at 10 mDa. For those tentatively iden-
tified metabolites with a fragmentation spectrum avail-
able, the similarity between the experimental
fragmentation spectrum obtained and the theoretical
ones was checked using the fragmentation pane tool of
PEAKVIEW software for in silico fragmentation and also
searching on the scientific literature. Only candidates
whose presence in humans was likely were selected as
possible novel MM biomarkers.
2.14. Statistical analysis
For Mel1 characterization, all data are presented as
the mean  standard deviation. Differences between
groups were analysed for statistical significance using
the two-tailed Student’s t-test. P-value of 0.05 was
accepted as the statistical significance level.
3. Results
3.1. Characterization of primary Mel1
melanospheres
For the enrichment of melanoma CSCs, we used a pri-
mary patient-derived tumour cell line (Mel1) from an
MM skin biopsy (stage M1a). We studied the anchorage-
independent growth of Mel1 spheres in serum-free condi-
tions [28] to determine their CSC characteristic phenotype
by determining sphere-forming ability, proliferation rate
of primary and secondary melanospheres, clonogenic
capacity by colony-formation assay in soft agar, side pop-
ulation, CD20 and CD44 cell surface markers’ expression
and ALDH activity (Fig. 1).
Cells growing as melanospheres had a significantly
lower proliferation rate when compared to the adher-
ent cell culture of the same cell line, with a doubling
time for adherent cells, and primary and secondary
spheres of 31.6, 51.7 and 65.1 h, respectively (Fig. 1A,
B). Therefore, melanospheres showed the slow-cycling
nature of stem cell populations. Under anchorage-in-
dependent and serum-free conditions Mel1 cells had
the capacity of self-renewal by the increased sphere
number and size of melanospheres (Fig. 1A,C–E).
Although a significantly higher number of secondary
spheres were observed in comparison with primary
spheres (Fig. 1A,D), the size was smaller in secondary
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spheres than in primary spheres, with average diame-
ters of 5.6 and 0.8 mm, respectively (Fig. 1A,E).
Moreover, Mel1 melanospheres showed a high capac-
ity to form colonies in soft agar (Fig. 1C).
Accordingly, the rate of side population (SP) in mel-
anospheres was significantly higher than in adherent
cells (Fig. 1F). Thus, adherent cells displayed a 9.7%
of SP, whereas primary and secondary Mel1 melano-
spheres showed 17.5% and 24.5%, respectively. More-
over, secondary spheres showed a significantly higher
proportion of cells expressing both CD20+ and CD44+
markers with values of 29% and 14.5%, respectively,
Fig. 1. Characterization of Mel1 CSCs. (A) Representative light microscopy (49) images of primary (left) and secondary (right)
melanospheres formed from Mel1 cell line; (B) proliferation curves of Mel1 adherent cells and melanospheres cultured for 3 days and
seeded with an equal number of cells at day 0; (C) representative optical image of the colonies formed by Mel1 cells coming from adherent
cells, primary and secondary spheroids after 37 days soft agar culture in P6 well plates; stained with 0.1% iodonitrotetrazolium chloride; (D)
number of primary and secondary spheres formed by Mel1 cell line growing in anchorage-independent and serum-free conditions. Spheres
were counted after 3 days under light microscopy; (E) diameter of primary and secondary spheres, measured by IMAGEJ software; (F) side
population determined in the different culture types; (G) percentage of CD20+ and (H) CD44+ in adherent cells and primary and secondary
melanospheres, and (I) percentage of ALDH+ cells measured by flow cytometry. Data are graphed as mean  SD from experiments carried
out in triplicates (***P < 0.001; **P < 0.01; *P < 0.05).
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in comparison with primary melanospheres (CD44+:
14%, CD20+: 9%) and cells growing in adherent con-
ditions, where only 1.5% and 5% were positive for
CD20 and CD44, respectively (Fig. 1G,H). Regarding
ALDH activity, both primary (8.1%) and secondary
melanospheres (26.9%) displayed a significantly higher
proportion of ALDH+ cells than the adherent ones
(4.8%) (Fig. 1I).
Altogether, these results indicate that Mel1 cells
growing as primary and secondary melanospheres in
anchorage-independent and serum-free conditions con-
stitute an enriched cell population with functional and
phenotypic stemness properties. Since secondary mela-
nospheres were most enriched in CSC properties, they
were used for subsequent studies.
3.2. Isolation and characterization of exosomes
derived from primary patient-derived Mel1 CSCs
and serum of patients with malignant melanoma
Based on their unique size and density, we isolated
exosomes from the culture supernatant of Mel1 sec-
ondary spheres and MMP serum following the ultra-
centrifugation protocol described in the Materials and
methods section. Exosome purification was confirmed
by TEM, AFM, western blot, NanoSight and SEM
(Fig. 2).
As shown in TEM images (Fig. 2A), vesicles
obtained from Mel1 secondary melanospheres have a
characteristic saucer-like ultrastructure with diameters
ranging from 40 to 210 nm and crescent-shaped mem-
brane invaginations limited by a lipid bilayer, while
vesicles obtained from MMP serum had a diameter
ranging from 30 to 140 nm (Fig. 2A). AFM images
showed a heterogeneous organization of exosomes, in
terms of the wide variation in shape and size as
demonstrated in both 2-dimensional (2D) images and
topographic profiles, regardless of their origin
(Fig. 2B). Western blot analysis showed that these
extracellular Mel1 vesicles were positive to known exo-
some classic markers including CD63, Alix and CD9
(Fig. 2C). Moreover, we were able to detect the
expression of the CD271 melanoma CSC marker in
both exosomes and Mel1 secondary melanospheres.
EVs isolated from serum of HCs and MMPs at differ-
ent stages of the disease (stages I–IV) were also posi-
tive for Alix and CD9 markers (Fig. 2C).
Exosome size distribution determined by NTA Soft-
ware confirmed the presence of particles with nano-
metric size in both types of samples, and the average
concentration was 5.48 9 108 particlesmL1 for Mel1
CSC-derived exosomes and 4.64 9 108 particlesmL1
for MMP serum-derived exosomes. Mel1 CSC-derived
exosomes showed peaks around 115 nm corresponding
to individual exosomes, while larger size peaks were
related to exosome aggregates (Fig. 2D), which was
also confirmed by SEM (Fig. 2E). The microanalysis
determined that the majority component was carbon,
which confirmed the organic origin of the samples
(Fig. 2E).
Furthermore, we were able to detect multivesicular
bodies with spheroid structures inside surrounded by a
phospholipid bilayer in Mel1 secondary melanospheres
(Fig. 2F). Finally, the morphology and size of exo-
somes were also verified by immunogold using beads
coated with an anti CD63 antibody. Black punctate
regions indicate a positive staining for CD63 around
the exosome membranes from both Mel1 CSC-derived
exosomes and MMP serum-derived exosomes
(Fig. 2G). Exosomes derived from Mel1 differentiated
adherent cells were also isolated and characterized
according to the same criteria (Fig. S1).
3.3. LC-HRMS metabolomic and chemometric
analysis of primary patient Mel1-derived
exosomes
Metabolomic characterization was first performed with
exosomes isolated from adherent Mel1 tumour cells
and from Mel1 CSCs. The HPLC-Q-TOF-MS total
ion chromatograms (TICs) observed in the positive
ionization mode for the metabolites extracted from
exosome samples showed excellent reproducibility in
terms of retention time and signal intensity, suggesting
a low analytical drift across the whole set of samples
(Fig. 3). A positive ionization data matrix of 2486
mass signals was obtained as an outcome of the peak
picking and alignment procedures. In order to filter
the results and minimize the signal redundancy, only
peaks representing monoisotopic ions (signals with the
lowest m/z value within an isotope pattern) were
selected (281 peaks) and subjected to the chemometric
analysis. After that, raw data were normalized, trans-
formed and scaled, and a first filtering by t-test and
twofold change was performed in order to discard
mass signals present in blank solvent samples and,
therefore, not exclusively present in biological samples.
After this filtering process, 138 candidates (5.5% of
total mass signals) were considered and selected as differ-
entially expressed in exosome samples versus mobile-
phase solvent samples. Next, ANOVA (P-value < 0.05)
and fold change (FC) > 1.5 filtering were performed for
multiple comparison on the three groups of samples (ad-
herent cells, primary spheres and secondary spheres), and
post hoc analysis using Tukey’s honestly significant dif-
ference (Tukey’s HSD) was applied to identify significant
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Fig. 3. Representative HPLC/MS total ion chromatograms (TICs) of metabolites present in exosomes derived from Mel-1 cell line. TIC
corresponding to representative exosome samples derived from (A) adherent cells, (B) primary melanospheres and (C) secondary
melanospheres, scanned by positive ion mode. The x-axis represents the chromatographic retention time, while the y-axis represents the
intensity. Methanol was used for metabolite extraction.
Fig. 2. Characterization of exosomes derived from Mel1 secondary melanospheres and MMP serums. (A) Transmission electron microscopy
images of isolated exosomes with a saucer-like shape limited by a lipid bilayer. EVs isolated from Mel1 secondary melanospheres culture
supernatants had diameters ranging from ~ 40 to 210 nm; those isolated from MMP in had a diameter ranging from ~ 30 to 140 nm.
Images show exosomes derived from an MMP at stage IV. Black arrowheads point to exosomes; (B) topography of exosomes derived from
Mel1 secondary melanospheres and MMP serum observed under atomic force microscopy (AFM). Exosomes on a mica surface revealed
heterogeneity in size and shape as well as forming aggregates in both 2-dimensional 2D (left) images and 3D profiles (right). Acquisition
areas were 5 9 5 µm2; (C) western blot analysis of CD9, CD63, Alix exosomal surface markers and the CD271 melanoma stem cell marker
in melanosphere-derived exosomes and Mel1 CSCs. The expression of CD9 and Alix is also shown as representative exosomal surface
markers in MMP serum-derived exosomes. IgG was used as a positive control; (D) the size distribution of exosomes obtained from Mel1
CSC and MMP serum was analysed by NTA; (E) scanning electron microscopy images of CSC-derived exosomes aggregated (left) and
individualized (right) and microanalysis of particles (down) showing the particle composition; (F) multivesicular bodies observed by electron
microscopy in Mel1 CSCs. Image obtained from paraffin sections; (G) immunogold using beads coated with an anti-CD63 antibody in
exosomes derived from Mel1 secondary melanospheres cultures (left) and from a stage IV MMP serum (right).
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metabolite changes. As an outcome, 19 differential m/z
signals met these criteria (Table S1). After the selection
of those differential m/z signals, samples were analysed
by principal component analysis (PCA) and partial least
squares discriminant analysis (PLS-DA). The PCA score
plot for all the analysed sample groups is shown in
Fig. 4A. The clustering or spreading of quality control
(QC) samples allows assessing the quality of the analyti-
cal system performance. Blank solvent (BS) samples were
clearly separated from biological samples (Fig. 4A). Exo-
some samples derived from adherent cells, and primary
and secondary spheres were clearly separated from each
Fig. 4. Metabolomic analysis of exosomes derived from Mel1 patient-derived cell line. (A) PCA score plots based on HPLC/MS data of
exosome samples derived from adherent cells (red), primary melanospheres (green), secondary melanospheres (blue), QC samples (yellow)
and BS samples (pink). (B) Heat map showing the significantly different metabolites when comparing exosomes derived from adherent cells
(red) and secondary melanospheres (blue). Each row on the heat map represent a unique metabolite with a characteristic mass-to-charge
ratio and retention time, while each column represents one exosome sample. The colour code represents the normalized intensity with
which each metabolite is detected. Blue represents a decreasing trend, while red represents a rising trend. (C) Chemical structure of
candidate biomarker 1-hexadecanoyl-sn-glycero-3-phosphocholine PC (16:0/0:0). (D) Chemical structure of candidate biomarker triacylglycerol
TG (18:2/22:3/22:4). (E) Chemical structure of candidate biomarker diacylglycerophosphoglycerol PG (20:0/12:0). (F) Chemical structure of
candidate biomarker glycerophosphoserine PS (P-16:0/15:1).
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other along the first principal component (PC1) and the
second principal component (PC2), which describe about
89.9% and 5.6%, respectively, of the total data variabil-
ity remaining after filtering. The group separation
observed in the PCA scores plot indicated a differential
pattern of the metabolites found in exosomes isolated
from adherent cells compared with primary and sec-
ondary spheres (Fig. 4A).
The PCA score plot for the three-group comparison
between exosomes derived from adherent cells, and
primary and secondary CSCs is shown in Fig. S2A,
while the corresponding heat map showing the differ-
ential abundance of those metabolites found as statisti-
cally different in those three comparison groups is
shown in Fig. S2B.
However, as can be clearly seen in the PCA score
plot, the greatest metabolic differences were found
between adhered cells and CSC melanospheres, but
not between primary and secondary spheres. For that
reason, a filtering by t-test (P-value < 0.05) and FC
(FC > 1.5) was also performed comparing adhered
cells with secondary sphere samples, as they were those
that possessed more stemness properties (Fig. 1).
When comparing these two groups, 19 differential m/z
signals also met these criteria (Table 1). Based on
PLS-DA models, exosome samples derived from
adherent cells and secondary spheres were discrimi-
nated with a R2 of 0.99 and a Q2 of 0.97, exceeding
the threshold values accepted in metabolomic experi-
ments (R2 > 0.7 and Q2 > 0.4) [33]. Accordingly, the
heat map displayed a clear differential pattern of
metabolite expression across samples of exosomes
derived from both Mel1 adherent cells and Mel1 sec-
ondary spheres (Fig. 4B).
3.4. Structural identification of selected
differential metabolites in primary patient Mel1
cells
Metabolite identification was carried out according to
the criteria explained in Materials and Methods section.
In addition, we established two identification levels: (1)
molecular formula matched with isotopic profile and
compound databases and (2) experimental fragmenta-
tion spectrum matched in spectral databases. As a
result, it was possible to assign the following tentative
identifications for differential peaks between exosome
samples derived from adherent cells and those derived
from CSC melanospheres (Table 2): m/z 496.3381
corresponds to the glycerophosphocholine PC 16:0/0:0
(http://www.lipidmaps.org/data/LMSDRecord.php?LMID
=LMGP01050018) (Fig. 4C); m/z 515.3962 corre-
sponds to the triacylglycerol TG (18:2/22:3/22:4) (http://
www.lipidmaps.org/data/LMSDRecord.php?LMID=
LMGL03012177) (Fig. 4D); m/z 729.5293 corresponds
to the diacylglycerophosphoglycerol PG (20:0/12:0)
(http://www.lipidmaps.org/data/LMSDRecord.php?
LMID=LMGP04010867) (Fig. 4E); and m/z 745.5143
corresponds to the glycerophosphoserine PS (P-16:0/
15:1) (http://www.lipidmaps.org/data/LMSDRecord.
php?LMID=LMGP03030006) (Fig. 4F).
We were not able to identify the rest of m/z signals or
assign them a biologically coherent molecular formula,
according to the same mentioned criteria and the identifi-
cation rules described by Kind and Fiehn [35].
The four tentatively identified and other nine
unidentified ions have significant differences between
the groups, being more abundant in exosome samples
derived from adherent cells compared with those from
secondary spheres. However, other six unidentified sig-
nals were more abundant in CSC Mel1-derived exo-
somes compared with those from adherent cells
(Fig. 4B).
Table 1. Differential metabolites found in the two-group
comparison between exosomes derived from adherent cells (ADs)
and secondary spheres (S2), in Mel1 patient-derived cell line
exosomes. m/z, mass-to-charge ratio; RT, retention time (min).
AD/S2a
m/z RT P-valueb FCc
313.2714 15.7 0.0318 1.7911 (↑)
316.3215 8.7 0.03372 0.6633 (↓)
357.1404 4.9 0.00163 11.1627 (↑)
378.3214 12.6 0.0008 0.3929 (↓)
388.2521 4.2 0.00685 1.5919 (↑)
399.2608 15.2 0.01546 1.8870 (↑)
415.2359 15.2 0.01587 1.8891 (↑)
425.136 7.2 0.01171 0.1966 (↓)
426.1372 7.0 0.00049 0.1124 (↓)
496.3409 11.6 6.48 9 105 4.1367 (↑)
507.4077 15.6 0.04807 3.1055 (↑)
515.3962 15.7 0.04258 2.2071 (↑)
530.1469 8.6 2.24 9 105 18.1682 (↑)
589.1461 5.2 0.04382 10.2656 (↑)
623.0031 1.3 0.00377 0.0106 (↓)
680.5277 15.6 0.04514 2.0574 (↑)
729.5293 15.7 0.04517 2.2063 (↑)
745.5143 15.7 0.04205 2.2513 (↑)




P-value corresponding to univariate statistical analysis (t-test). Only
peaks with a P-value < 0.05 were selected.
c
Fold change expressed as the ratio of the two averages (AD/S2).
Only peaks with a fold change > 1.5 or < 0.66 were selected. The
arrows indicate whether the metabolite is increased (↑) or
decreased (↓) in AD relative to S2.
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3.5. LC–HRMS metabolomic analysis of
exosomes derived from serum of patients with
MM
Analogously to Mel1-derived exosomes, we carried out
a metabolomic analysis in the same experimental con-
ditions with the aim of exploring metabolomic differ-
ences between serum-derived exosomes from MMPs at
different stages of the disease and HCs. As an out-
come, 93 differential (t-test P-value < 0.05 and
FC < 1.5) m/z signals were found. These signals were
analysed by PCA and PLS-DA, obtaining a clear sepa-
ration of exosome samples derived from MMP and
HC serum within the PCA score plot along PC1 and
PC2 (Fig. 5A), which describe about 73.7% and
14.2%, respectively, of the total data variability. In
PLS-DA models, exosome samples derived from MMP
and HC serum were discriminated with an R2 of 0.99
and Q2 of 0.98.
Due to the greater complexity of the patient-derived
serum composition, we found a larger number of dif-
ferentially expressed metabolites compared with Mel1
primary cell line. Since metabolite identification is the
most laborious and time-consuming task in the meta-
bolomic workflow, we applied the variable importance
in projection (VIP) technique as an additional indepen-
dent variable selection method in order to achieve a
more affordable set of metabolites in terms of identifi-
cation [36]. Following the greater-than-one rule, which
is usually considered for detecting variables with the
greatest importance in the projection [36], 24 differen-
tially expressed metabolites were selected (Table 3).
The heat map representing the differential abundance
of these selected metabolites between exosome samples
derived from MMPs and HCs is shown in Fig. 5B. As
can be observed, 23 metabolites were more abundant
in exosome samples derived from HCs, compared with
those from MMPs, and only 1 metabolite (not identi-
fied) was higher in MMPs in comparison with HCs
(Fig. 5B, Table 3). Interestingly, the metabolite with
m/z 496.3381, identified as 1-hexadecanoyl-sn-glycero-
3-phosphocholine (PC 16:0/0:0), was found to be over-
expressed in exosomes derived from both HC serum
and adherent Mel1 cells, compared with MMP serum
and CSC Mel1 cells, respectively.
Additionally, the area under the curve (AUC) values
were calculated from receiver operating characteristic
(ROC) curve analysis in order to assess the potential
clinical utility of the previously selected metabolites,
displaying all values close or equal to 1, which suggest
they could be considered as potential diagnostic
biomarkers. Some of those selected differential peaks
between the exosome samples derived from MMPs
and those derived from HCs were tentatively identified
(Table 3). Following the same criteria previously
described, we established two identification levels. Fig-
ure 5C,D shows the chemical structure and the corre-
sponding interpretation of fragmentation spectrum of
m/z 496.3381 identified as PC 16:0/0:0, as an example
of one of those tentatively identified metabolites. For
some of the m/z signals, a tentative identification was
not possible following the same criteria [35]. However,
they could also be considered as potential biomarkers,
since all of them showed high AUC values.
4. Discussion
Metastatic melanoma is the most aggressive and life-
threatening form of skin cancer. Despite advances in
its treatment, the incidence rate and mortality have
continued increasing worldwide over the past few dec-
ades. Therefore, there is an urgent need for further
Table 2. Differential metabolites tentatively identified in Mel1 patient-derived cell line exosomes based on MS/MS fragmentation spectra
and database search. m/z, mass-to-charge ratio; RT, retention time (min).
m/z RT Tentative IDa Molecular formulab Mass errorc P-valued FCe ILf
496.3381 11.61 LPC (16:0) C24H50NO7P 3 6.48 9 10
5 4.1367 (↑) 2
515.3962 15.72 TG(18:2/22:3/22:4) C65H108O6 0 0.04258 2.2071 (↑) 2
729.5293 15.71 PG(20:0/12:0) C38H75O10P 4 0.04517 2.2063 (↑) 2
745.5143 15.70 PS(P-16:0/15:1) C37H70NO9P 2 0.04205 2.2513 (↑) 2
a
Common name of the tentatively identified metabolite according to MS/MS fragmentation spectra and database search.
b




P-value corresponding to univariate statistical analyses (t-test). Only peaks with a P-value < 0.05 were selected.
e
Fold change expressed as the ratio of the two averages (AD/S2). Only peaks with a fold change > 1.5 or < 0.66 were selected. The arrows
indicate whether the metabolite is increased (↑) or decreased (↓) in AD relative to S2.
f
Identification level: (1) molecular formula matched in compound databases and (2) experimental fragmentation spectrum matched in spectral
databases.
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understanding of the underlying mechanisms of this
neoplasia, and for discovering clinically useful
biomarkers. The diagnosis of MM currently remains
challenging and the procedure is still invasive, expen-
sive and time-consuming, since it requires the removal
and analysis of the primary melanoma, detection of
Fig. 5. Metabolomic analysis of serum-derived exosomes from both patients with malignant melanoma and healthy individuals. (A) PCA
score plots based on HPLC/MS data of serum-derived exosome samples from MMPs (red), HCs (blue), QC samples (yellow) and BS
samples (pink). (B) Heat map showing the changing intensity patterns of significantly different metabolites of two-group comparison:
exosome samples derived from MMPs (red) versus exosomes derived from HCs (blue). (C) Chemical structure of candidate biomarker 1-
hexadecanoyl-sn-glycero-3-phosphocholine PC (16:0/0:0); (D) representative fragmentation spectrum of candidate biomarker PC (16:0/0:0).
Within the product ion spectra arising from the [M + H]+ ions of this molecule, different specific fragments were found, such as the m/z
184, 104, 258, 321 or 478 ions, corresponding to characteristic molecule fragments.
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high-risk markers and sentinel lymph node biopsy to
determine the presence and stage of metastatic disease
[37]. There are several promising tissue and serological
biomarkers for predicting melanoma progression and
overall patient survival [38]. Among the serological
biomarkers, only S100 calcium-binding protein B
(S100B) and lactate dehydrogenase (LDH) have some
value for predicting progression to an advanced stage
of the disease but do not translate into adequate thera-
peutic intervention and survival [39]. However, there
are currently no reliable serum-derived biomarkers for
early detection of the disease or prognostic markers
for early-stage melanoma patients. This underscores
the need to identify reliable noninvasive blood-based
biomarkers that allow an economical, rapid and stan-
dardized detection of MM in its earliest stages, the
identification of patients at the highest risk of meta-
static recurrence and the prediction of their treatment
response in order to improve patient outcome.
In this context, exosomes represent a novel source
of noninvasive biomarkers since they and their cargo
can be easily isolated from most body fluids using
minimally invasive techniques [40]. They are consid-
ered as a subtype of sEVs, which may comprise exo-
somes and other small-sized vesicles sharing densities
and markers [7]. To date, it is known that the compo-
sition of sEVs is not a random sample of cell content,
but rather is assembled by a highly selective process
Table 3. Potential biomarkers differentially expressed in MMP compared with HC serum-derived exosomes based on MS/MS fragmentation
spectra and database search. m/z, mass-to-charge ratio; RT, retention time (min).




errorc P-valued FCe AUCf VIPg ILh
380.2551 9.64 Sphingosine-1-phosphate C18H38NO5P 2 1.31 9 10
13 3.57 (↑) 1 1.03 2
400.3419 10.19 Palmitoylcarnitine C23H45NO4 1 9.71 9 10
16 6.07 (↑) 1 1.26 2
426.3570 10.41 Elaidic carnitine C25H47NO4 2 2.54 9 10
14 3.44 (↑) 1 1.13 2
438.2987 11.69 PE(P-16:0/0:0 C21H44NO6P 2 4.74 9 10
19 5.18 (↑) 1 1.33 2
454.2902 11.20 PE(16:0/0:0) C21H44NO7P 6 1.99 9 10
09 3.72 (↑) 1 1.23 2
466.3302 13.55 Glycerophospholipid-related
compound
C23H48NO6P 2 1.16 9 10
15 3.31 (↑) 1 1.18 1
477.2309 3.99 – – – 2.33 9 1024 9.84 (↑) 1 1.36 –
480.3080 11.64 PE(18:1/0:0) C23H46NO7P 1 2.11 9 10
09 3.33 (↑) 1 1.23 2
482.3251 12.95 PE(18:0/0:0) C23H48NO7P 2 5.19 9 10
10 3.71 (↑) 1 1.45 2
482.3585 11.71 PC(O-16:0/0:0) C24H52NO6P 4 1.11 9 10
12 2.54 (↑) 1 1.1 2
496.3391 11.28 LPC (16:0) C24H50NO7P 1 1.18 9 10
06 3.89 (↑) 0.99 2.28 2
502.2917 10.68 PE(20:4/0:0) C25H44NO7P 2 1.24 9 10
10 3.25 (↑) 0.99 1.15 2
516.3009 4.17 Taurallocholic acid C26H45NO7S 4 7.39 9 10
28 22.23 (↑) 1 1.72 1
521.2544 4.17 – – – 3.90 9 1027 22.86 (↑) 1 1.6 –
522.3551 11.47 PC(18:1/0:0) C26H52NO7P 1 3.83 9 10
06 2.40 (↑) 0.96 1 2
524.3698 12.76 PC(18:0/0:0) C26H54NO7P 2 3.95 9 10
08 4.00 (↑) 0.98 1.57 2
526.2902 10.47 PE(22:6/0:0) C27H44NO7P 5 2.60 9 10
13 3.82 (↑) 1 1.06 2
564.3588 4.49 Ganglioside GM3 (d18:0/14:0) C55H102N2O21 5 5.80 9 10
12 2.19 (↑) 0.99 1.07 1
565.2809 4.32 – – – 8.84 9 1028 13.19 (↑) 1 1.58 –
604.3544 4.46 Presqualene diphosphate C30H52O7P2 0.6 4.46 9 10
29 24.62 (↑) 1 1.99 1
608.3849 4.61 – – – 1.37 9 1011 2.33 (↑) 0.99 1.08 –
632.3827 4.46 – – – 1.20 9 1028 44.92 (↑) 1 1.58 –
733.3346 4.15 – – – 1.08 9 1007 0.13 (↓) 0.95 1.02 –
736.4321 4.76 Glycerophospholipid-related
compound
C38H68NO8P 1 4.47 9 10
29 52.18 (↑) 1 1.97 1
a
Common name of the tentatively identified metabolite according to MS/MS fragmentation spectra and database search.
b




P-value corresponding to univariate statistical analyses (t-test). Only peaks with a P-value < 0.05 were selected.
e
Fold change expressed as the ratio of the two averages (HC/MMP). Only peaks with a fold change > 1.5 or < 0.66 were selected. The
arrows indicate whether the metabolite is increased (↑) or decreased (↓) in HC relative to MMP.
f
Area under the curve corresponding to ROC curve analyses.
g
VIP value corresponding to variable importance in the projection selection technique.
h
Identification level: (1) molecular formula matched in compound databases and (2) experimental fragmentation spectrum matched in spec-
tral databases.
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whose nature remains unclear [41]. Moreover, while in
some instances the antigens found on the surface of
microvesicles (e.g. lineage markers) could resemble
those of their producing cells [42], several studies sug-
gest that, especially, exosomes contain a more unique
protein and RNA cargo. Thus, exosomes tend to be
enriched in glycoproteins compared with the secreting
cells [43]. In addition, sEVs imperatively comprise a
lipid moiety, and their phosphatidylserine, cholesterol,
sphingomyelin and glycosphingolipid content is richer
than their cellular sources [44,45]. Thus, the studies
that originally reported their presence in blood deter-
mined that the sEV membrane could support the coag-
ulation cascade by exposition on their surface of
phosphatidylserine [46]. Furthermore, sEVs also inter-
act with secreted phospholipases to generate eicosa-
noids, which regulate the transfer of cargo into a
cellular recipient. Eicosanoids, potent bioactive lipid
mediators, are useful as biomarkers and contribute to
a variety of biological functions, including modulation
of distal immune responses, angiogenesis and tumour
progression in cancer context [47]. The role of the vari-
ous lipidic pathways is crucial in the biogenesis and
functions of microvesicles and exosomes. For instance,
tumour-derived exosomes enriched in prostaglandins
and free fatty acids (including arachidonic acid) partic-
ipate in the formation of a favourable microenviron-
ment for tumour growth [48]. In this context, sEVs
contribute with their lipid molecules or their lipid-re-
lated enzymes to several pathophysiologies, playing an
important role in cancer [49].
Exosomes are actively secreted by cancer cells at a
higher rate than by normal cells. In particular, mela-
noma cells seem to produce a large quantity of these
microvesicles [50], in contrast to normal melanocytes
[51]. Moreover, a melanoma-specific exosomal signa-
ture, which correlates with tumour burden and metas-
tasis, was identified in blood from patients with MM
at stage IV [14]. Malignant melanoma is characterized
by an extraordinary heterogeneity, propensity for dis-
semination to distant organs and resistance to
chemotherapy, which results from the unique charac-
teristics of melanoma CSCs [52].
In this study, we have set up a broadly applicable
approach for metabolomic profiling of exosomes iso-
lated from cell culture media of Mel1 melanoma CSCs
and from serum of patients with MM at different
stages in order to identify potential clinically useful
biomarkers with prognostic/diagnostic value. First, we
confirmed that the primary Mel1 cell line obtained
from a metastatic MM growing in serum-free and
anchorage-independent conditions displayed both
CSC-like functional and phenotypic properties. Mel1
cells growing as spheres possess self-renewal ability
and clonogenicity. The spheres were enriched in cells
with high ALDH activity, overexpressing CD20 and
CD44 surface markers and presenting a great SP rate.
All these properties have been described as characteris-
tics of CSCs [29]. The isolation of exosomes from cell
culture supernatant was performed by ultracentrifuga-
tion and confirmed by TEM, AFM and western blot
assays. Next, we characterized their size by NanoSight
showing particles with diameters of around 100 nm,
confirming the specific enrichment in exosomes [14,17].
Mel1 exosomes were positive for CD9, CD63 and Alix
exosomal markers, and also for CD271 melanoma
CSC marker. Previous studies on patients with mela-
noma have shown that CD271+ is a good candidate
marker to unequivocally identify CSC subpopulation
[53]. However, it is important to highlight that, based
on the exosome isolation and characterization proto-
cols carried out in this study, the term ‘exosomes’
applied in this work actually refers to sEVs, a general
term proposed in the ‘MISEV’ guidelines [7], compris-
ing exosomes but also other vesicles which share size,
density and markers.
The metabolomic profile of exosomes analysed
through MS revealed significant differences in the
metabolomic fingerprint of exosomes derived from
CSCs as compared to tumour adherent (more differen-
tiated) cells in Mel1 MM primary cell line and also in
the exosomes derived from MMPs at different stages
compared with HCs. ROC curves are frequently used
in biomedical informatics research to evaluate classifi-
cation and prediction models for decision support,
diagnosis and prognosis. Thus, it is possible within a
metabolomic study to calculate ROC curves for each
potential biomarker in order to assess its potential
clinical utility in terms of AUC [34]. In this regard, we
calculated the AUC for each selected candidate
biomarkers in patients’ serum-derived exosomes, and
we obtained values close or equal to 1. Considering
that AUC values over 0.8 indicate a good predictor
model, our results (Tables 1 and 3) suggest that these
metabolites could be used as a panel of clinically use-
ful biomarkers.
Metabolic reprogramming is firmly established as a
hallmark of cancer [54], and lipids have been described
to exert multiple biochemical functions during cancer
development. Several lipids, including sterols, di-/tria-
cylglycerols and phospholipids, are integral part of
biological membranes and are also used for energy
storage, production and cellular signalling. Fatty acids
(FAs) are indispensable for lipid biosynthesis. Disrup-
tion of lipid metabolism, especially FA synthesis
(FAS) and fatty acid oxidation (FAO), has become
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increasingly recognized as an important metabolic
rewiring phenomenon in tumour cells [55]. Glycolipids
and phospholipids (phosphatidylcholine and phos-
phatidylethanolamine) along with cholesterol are
major components of biological membranes and mark-
edly influence membrane fluidity [55]. In addition to
their structural roles, lipids also orchestrate signal
transduction cascades and can also be broken down
into bioactive lipid mediators, which regulate several
carcinogenic processes, such as cell growth, cell migra-
tion and metastasis [56].
In our study, we found a decreased expression
between exosome samples derived from CSC melano-
spheres and those derived from adherent-differentiated
tumour cells of four tentatively identified metabolites
from different lipid classes, such as glycerophospho-
glycerols [PG(20:0/12:0)], glycerophosphoserines [PS(P-
16:0/15:1)], triacylglycerols [TG(18:2/22:3/22:4)] and
glycerophosphocholines (PC 16:0/0:0). Interestingly,
we found that PC 16:0/0:0 expression was reduced in
both Mel1 CSCs and MMPs in comparison with Mel1
differentiated tumour cells and HCs, respectively. In
line with these results, previous studies reported the
reduced expression of PC 16:0/0:0 associated with
malignant diseases, such as colorectal cancer [57],
digestive tract tumours or renal cell carcinoma [58].
Moreover, higher levels of other glycerophospholipids
such as LysoPC 18:0/0:0 have been consistently related
to lower risks of breast, prostate and colorectal cancer
[59]. Other studies have shown that the serological lipi-
domic profile of prostate cancer patients revealed sev-
eral putative lipids that might serve as diagnostic
biomarkers of this neoplasm [60].
The metastatic potential of cancer cells correlates
with the expression of genes involved in fatty acid syn-
thesis, oxidation and intracellular lipid storage. It has
been shown that enzymes involved in lipid metabolism
play a role in metastasis. For example, stearoyl-CoA
desaturase (SCD) and long-chain fatty acyl synthetase
(ACSL) 1 and 4 cooperate to induce epithelial-to-mes-
enchymal transition resulting in an increased invasion
potential of colon cancer cells [61]. Furthermore, it has
been suggested that the rapid extracellular hydrolysis
of phospholipids like PC 16:0/0:0 by metastatic
tumour cells and the subsequent cellular uptake of the
resulting free fatty acids (FFAs) seems to be a neces-
sary prerequisite for metastatic potential of epithelial
tumour cells, probably for generating pro-metastatic
lipid second messengers [62].
In this work, we also detected significant differences
in other metabolites in the serum-derived exosomes
from HCs compared with MMPs. For example, we
found lower levels of the lysophospholipid sphingosine
1-phosphate (S1P) in serum-derived exosomes from
MMPs than in HCs. This is consistent with previous
studies that had suggested this molecule as a potential
serum biomarker for hepatocellular carcinoma (HCC)
diagnosis, which was also found to be lower in HCC
patients [63]. Other differential metabolites that were
lower in MMP serum-derived exosomes were palmi-
toylcarnitine and elaidic carnitine. Recently, the role
of the carnitine system has been described in the meta-
bolic plasticity phenomenon, a mechanism through
which cancer cells are able to become more aggressive
and metastasize [64]. In agreement with our results, a
similar previous study, aimed at characterizing the
metabolomic serum profile of HCC patients in a Kor-
ean prospective cohort, also showed lower levels of
palmitoylcarnitine in HCC patients, compared with
healthy individuals [65]. Another metabolomic study
reported the potential use of this metabolite, among
others, as a predictive serum biomarker in non-small
cell lung cancer [66]. We also found lower levels of
several phospholipid-related compounds such as phos-
phatidylcholines (PCs) and phosphatidylethanolamines
(PEs) in MMP exosomal extracts versus HC extracts
(see Table 3). Changes in specific phospholipid (PL)
levels in tissues, cells and body fluids such as urine,
plasma or serum have clearly been demonstrated to be
associated with cancer [67]. Yang et al. suggested that
specific differential PLs found in the plasma of breast
cancer patients could be useful for diagnosis purposes
[68], and Waki et al. also reported PL differences in
breast CSCs and non-stem cancer cells (NSCCs) [69].
In colorectal cancer, decreased LPC levels in serum
patients have potential for use as diagnosis biomarkers
[70], since lower LPC levels could be associated with
the loss of body weight and inflammation, but could
also indicate a higher LPC decomposition rate to sup-
port cancer metabolism. Another study showed that
some PL species, including LPC (16:0), LPC (18:0),
PC (16:0) and PC (18:0), were significantly less present
in HCC and LC (liver cirrhosis) patients, compared
with HCs [71]. Another tentatively identified metabo-
lite, also found at lower levels in serum-derived exo-
somes from MMPs, is the glycosphingolipid
ganglioside GM3 (d18:1/16:00), a component of cell
plasma membrane that modulates cell signal transduc-
tion events. It has been reported that GM3 downregu-
lates the invasiveness capacity of human bladder
cancer cells and also that exogenously added GM3 can
prevent haptotactic cell migration in colorectal cancer
cell lines [72]. For the rest of metabolites, it was not
possible to give an accurate mass or MS/MS spectra-
based putative identifications using several databases.
This still represents a major challenge in the field of
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metabolomics. However, it could be clinically useful to
explore exosome-associated metabolomic m/z signa-
tures related to several stages of MM. All these results
found in both patients and CSCs suggest the impor-
tance of structural lipids detected in exosomes of
patients with MM as biomarkers in early detection of
patients with a high risk of MM and their potential in
the determination of aggressiveness or therapeutic
monitoring. However, since these results have been
obtained from a limited number of patients, further
studies with higher number of MMPs are necessary.
5. Conclusions
In conclusion, to our knowledge, this is the first metabo-
lomic-based study aimed at characterizing the cargo and
composition of exosomes secreted by melanoma CSCs,
in order to identify diagnosis and prognosis biomarkers
of MM progression. Our results provide evidence for
using MS to detect exosome lipid metabolites as a rich
source of biomarkers’ discovery for use in translational
research and precision medicine in oncology.
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